TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the uterine cervix~  * Advanced disease (stage IVB)~ * Persistent or recurrent disease~* No available curative treatment options~* Measurable disease by physical examination, chest x-ray, CT scan, or MRI~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* GOG 0-2~Life expectancy~* More than 6 months~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Hemoglobin \> 8 g/dL~Hepatic~* Bilirubin normal~* SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal OR~* Alkaline phosphatase ≤ 4 times ULN AND SGOT and SGPT normal~Renal~* Creatinine \< 1.5 times ULN~Other~* No other invasive malignancy within the past 5 years~* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No peripheral neuropathy \> grade 1~* No other concurrent malignancy except curatively treated non-melanoma skin cancer~* No other serious medical or psychiatric illness that would preclude giving informed consent or limit survival~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent biologic therapy~Chemotherapy~* No more than 2 prior chemotherapy regimens~  * One sensitizing chemotherapy regimen during radiotherapy AND 1 regimen for recurrent disease are considered 2 regimens~* At least 4 weeks since prior chemotherapy~* No prior docetaxel~* No prior carboplatin~* No other concurrent chemotherapy~Endocrine therapy~* At least 4 weeks since prior hormonal therapy~Radiotherapy~* See Chemotherapy~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy~Surgery~* At least 3 weeks since prior major surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years~* A diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)~* Willing and able to participate in all required evaluations and procedures in this study~Exclusion Criteria:~* Any evidence of prior SARS-CoV-2/COVID19 infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (biospecimen collection, medical record review) (Type: None): For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed.~For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiosurgery for Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histopathologically confirmed newly diagnosed glioblastoma multiforme or Anaplastic Glioma (WHO Grade III) by surgical excision or biopsy.~2. Patient must recover from the effects of surgery, post-operative infection, or other complications.~3. Therapy should start within 5 weeks of surgery~4. Must have an estimated survival of \> 8 weeks.~5. KPS \< 70.~6. Age \> 65 years.~7. Must have a pre- and post operative contrast enhanced MRI scans~8. Laboratory values within the following limits: ANC (absolute neutrophil count) \>/= 1500 cell/ul Platelets \>/= 100x 10(3)/ul, Hemoglobin \>/= 9g/dl, Serum Creatinine ≤ 1.5mg/dl., Serum total Bilirubin \</= 1.5 x upper limit of normal (ULN), SGOT/SGPT \</= 2.5x ULN, Albumin \>/= 3g/dl.~   -~Exclusion Criteria:~1. Histology grade less than Anaplastic Glioma ( WHO Grade III).~2. Recurrent malignant glioma.~3. Tumor involving the Brain stem.~4. Any detected tumor foci beyond the cranial vault.~5. Major medical or psychiatric illness, which in the investigator's opinion will prevent administration or completion of the protocol therapy.~6. Prior malignancies, except for non-melanomatous skin cancers, or carcinoma in situ of uterus, cervix or bladder, unless disease free for \> 5 years.~7. Prior chemotherapy for the current disease.~   -

- Gender: ALL
- Minimum Age: 66 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyberknife (Type: OTHER): Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsed/Refractory AML patients~2. Positive for any of CD33, CD38, CD56, CD117, CD123, CD34, or Muc1.(cytology, genetic testing)~3. Estimated survival time is more than 3 months in multiple myeloma,and Karnofsky Performance Status（KPS) score is more than 80.~4. No cytapheresis and cell separation contraindication.~5. Hemoglobin is more than 80 gram per litre.~6. The function of important organ was satisfied:(1)cardiac ultrasound indicated that cardiac ejection fractions is more than 50%（EF≥50%）, and the electrocardiogram showed no obvious abnormality;(2)Blood oxygen saturation is more than 90%（SpO2≥90%）;(3)Creatinine（Cr） is less than 2.5 times the upper limit of normal;(4)Alanine transaminase（ALT）and glutamic-oxalacetic transaminase（AST）is less than 3 times the upper limit of normal,and total bilirubin is less than 2 milligram per deciliter(TBil≤2.0mg/dL).~7. After discussion by the expert group, the patient's condition was analyzed and combined with the general physical condition of the patient, the benefit of participating in the clinical trial was greater than the risk.~8. Volunteered for this clinical trail and signed a consent form .~9. Currently, chemotherapy and approved targeted therapies are ineffective for the patients.Or patients cannot tolerate current chemotherapy.~Exclusion Criteria:~1. Active other disease and cannot control after treatment.~2. Patients with actively infection of Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).~3. Severe psychiatric disorder or other disease in central nervous system.~4. Patients are infected with fungus,bacteria or virus,and are difficult to control after treatment.~5. Patients with infection of HIV .~6. Pregnant or lactating women.~7. Patients who have Graft-Versus-Host Disease (GVHD) should receive systemic administration of immunosuppressive agents.~8. Patients have received other genetic therapy products.~9. Patients who have received systemic administration of glucocorticoid agents in one week before CART therapy.~10. Any situation may do harm to the subjects or interfere the results.~11. Have had Prolonged QT interval or severe heart disease in the past.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CART therapy in Acute myeloid leukemia (Type: EXPERIMENTAL): In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Acute primary ICH demonstrated with CT scan, within 6 h of symptom onset.~* Two systolic BP measurements ≥140 mmHg recorded \>2 min apart to qualify for enrolment.~* Onset ≤ 24 h prior to randomization~Exclusion Criteria:~* Contraindication to BP reduction i.e., severe arterial stenosis or high-grade stenotic valvular heart disease~* Indication for urgent BP reduction i.e., hypertensive encephalopathy, or aortic dissection~* Definite evidence that the ICH is secondary to underlying cerebral or vascular pathology, i.e., AVM, aneurysm, tumour, trauma, vasculitis, or hemorrhagic transformation of an ischemic infarct~* Previous ischemic stroke within 90 days of current event NB: Prior ICH is not an exclusion criterion~* Patients with suspected secondary cause of ICH.~* Planned surgical resection of hematoma NB: Extraventricular Drain placement is not an exclusion criterion~* Contraindication to CT perfusion imaging (i.e. contrast allergy, metformin use or Creatinine \>160 μmol/l)~* Patients with pre-existing disability and dependence (defined as a pre-morbid modified Rankin Scale score ≥3) will be excluded~* Patients with life expectancy \<6 months due to pre-morbid conditions/terminal illness~* Patients with known definite contraindications to MRI (pacemaker, ferrous metallic foreign body)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Target systolic BP <140mmHg (Type: EXPERIMENTAL): Systolic blood pressure will be reduced to \<140 mmHg within 1 hour of randomization.
- Target systolic BP <180mmHg (Type: ACTIVE_COMPARATOR): Systolic blood pressure will be reduced, to \<180 mmHg within 1 hour of randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or more with laboratory evidence of HIV-1 infection~* Received combination antiretroviral therapy (minimum of 2 agents)~* Antiretroviral regimen should be stable for at least 12 weeks prior to entry with no changes planned during the first 48 weeks. For subjects not on antiretroviral therapy at entry there should be no intent to commence therapy in first 24 weeks.~* Moderate or severe facial lipoatrophy and lipodystrophy at one or more other sites~* Provide written, informed consent.~Exclusion Criteria:~* Active AIDS-defining illness including active HIV wasting~* Active herpes labialis or any acute or currently present chronic skin disease (infection/inflammation) on/near area to be treated~* Currently on anticoagulants or any coagulopathy that would preclude safe deep subcutaneous injections~* Women: pregnant, breastfeeding or have positive pregnancy test or not willing to use adequate contraception if of child-bearing potential~* Concomitant therapy with anabolic steroids (except testosterone replacement), corticosteroids at greater than replacement doses, growth hormone or any currently available or experimental agent to improve appetite or weight~* Testosterone replacement for less than 6 months or at greater than replacement doses~* Subjects who have discontinued any prohibited concomitant agent/s must cease this therapy at least 30 days prior to screening.~* Prior use of any facial dermal filling/tissue expansion agent/s~* Any condition which may interfere with ability to comply with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate (Type: EXPERIMENTAL): poly-L-lactic acid injections
- Delayed (Type: ACTIVE_COMPARATOR): poly-L-lactic acid injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and/or female subjects \>=55 years of age~* Subfoveal choroidal neovascularization complicating age-related macular degeneration~* Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent in accordance with institutional and regulatory guidelines~Exclusion Criteria:~* Other serious ocular diseases or conditions, including diabetic retinopathy and glaucoma, that are likely to compromise visual acuity within 1 year

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1.18 years of age or older.~2.Male or nonpregnant, nonlactating females.~3.Diagnosis of Ulcerative Colitis for at least 3 months prior to screening.~4.Moderately to severely active Ulcerative Colitis (total Mayo Clinic Score ≥ 6), with objective evidence of inflammation defined by a Mayo endoscopic subscore (MES) ≥ 2 and disease extending \> 15 cm from the anal verge.~5.Physician plans to administer Janus Kinase inhibitor for at least 8 weeks of induction therapy as part of Standard of Care (SOC).~6.Documentation of a negative test result for latent tuberculosis within the last 12 months, or according to routine clinical practice.~7.Able to participate fully in all aspects of this clinical trial, including collection of tissue biopsies.~8.Written informed consent must be obtained and documented.~Exclusion Criteria:~1. Diagnosis of Crohn's disease or indeterminate colitis.~2. An active, serious infection, including localized infections.~3. Concomitant administration of biological therapies for Ulcerative Colitis or potent immunosuppressants, such as azathioprine and cyclosporine. Subjects with previous exposure to these treatments should undergo an appropriate washout period according to local practice prior to starting Janus Kinase inhibitor, in keeping with routine clinical practice.~4. Hematology laboratory (e.g., absolute lymphocyte count, absolute neutrophil count, and hemoglobin that contraindicate the product label.~5. Interval between live vaccinations and initiation of tofacitinib therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.~6. Serious underlying disease other than Ulcerative Colitis that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label Group (Type: None): Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Programmed abdominal or thoracic surgery~* Patients \> 18 yrs~* Patients are aware of German language~* Participation is voluntary~* ASA-risk class 1-2 (American Society of Anesthesiologists guidelines)~Exclusion Criteria:~* Severe cardiac, pulmonary, renal or neurologic disease~* ASA risk III and IV~* Insulin dependent Diabetes mellitus~* Polyneuropathy~* Chronic pain~* Use of analgesic drugs~* Ulcus duodeni~* Ulcus ventriculi~* Time after intestinal bleeding~* Allergy reactions towards coxibes or coxibe-like drugs~* Pregnancy and lactation~* Severe hepatic disease (Albumin \< 25 g/l or Child-Pugh-Score ≥ 10)~* Children and Teenager \< 16 years~* Chronic intestinal inflammation~* Heart failure (NYHA II - IV)~* Inbalancend arterial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preemptive (Type: ACTIVE_COMPARATOR): Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
- Postoperative (Type: PLACEBO_COMPARATOR): Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of mild to moderate hypertension, or newly diagnosed hypertension, defined as seDBP ≥90 mmHg and \<110 mmHg and seSBP \<180 mmHg~* Withdrawal of all previous antihypertensives prior to the single-blind placebo run-in period and the double-blind treatment period~Exclusion Criteria:~* Secondary hypertension (e.g., renal, renovascular, or adrenocortical disease, pheochromocytoma, Cushing's syndrome, primary aldosteronism, iatrogenic), severe hypertension, or malignant hypertension~* The patient cannot withdraw from antihypertensives by any route including diuretics, alpha-blockers, betablockers, calcium channel blockers, ACE-I, ARB, or other medications affecting blood pressure; patients who have stable angina and have not had their nitrate dosage changed within the past three months (i.e., on a stable maintenance dose) are eligible for this study; sildenafil citrate, theophylline, or papaverine must not be taken within 24 hours prior to a clinic visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone group (Type: EXPERIMENTAL): None
- Losartan group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical indication for cardiac catheterization and SVG angiography~2. Presence of at least one SVG lesion of 30% to 60% diameter stenoses, by visual estimation, which is not the culprit lesion\* responsible for the clinical syndrome of the patient~   \*If the target lesion is located in the same SVG than the culprit lesion (if present) it has to be at least 4 cm far from the stented segment)~3. Written informed consent~Exclusion Criteria:~1. Patient \< 18 years old~2. Ejection fraction \< 30%~3. Renal insufficiency with creatinine \> 200 μmol/l~4. Presence of more than 2 moderate SVG stenoses in a single SVG or significant diffuse SVG disease defined as disease covering more than half of the length of the SVG~5. Presence of more than 2 SVGs with moderate SVG stenoses~6. Unsuccessful angioplasty (residual stenosis \>30% and/or TIMI flow \<3) of any other lesion treated during the same procedure (culprit lesions will be treated before patient randomization)~7. Any significant complication occurring during the angioplasty of the culprit lesion(s) during the same procedure~8. SVG lesion located at the distal anastomosis~9. SVG lesions located at the proximal anastomosis (lesion length \< 5 mm from the SVG ostium)~10. Lesion length \>25 mm~11. SVGs ≤ 3 years ago~12. Cardiogenic shock~13. Remaining coronary or SVG lesion(s) with treatment (PCI or CABG) planned within the following year~14. Pregnancy~15. Contraindication to aspirin and/or thienopyridine/ticagrelor treatment~16. Allergy to paclitaxel~17. Any disease with a limiting life-expectancy (less than 2 years)~18. Need for chronic anticoagulation treatment~19. Definite presence or high suspicion of thrombus or ulceration in the target lesion~20. Target lesion located in the same SVG as the culprit lesion (if present) and distance between the target lesion and the most proximal or distal part of the stent implanted at the culprit lesion \< 4 cm~21. Vein graft diameter \< 2.5 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-stenting (Type: EXPERIMENTAL): Stenting the moderate SVG lesion with the paclitaxel stent
- Standard medical treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues